One Stop Solution For In-Depth Market Research Reports
詳細な市場調査レポートのワンストップソリューション
[Report Description]
Global Lidocaine Market is valued at approximately USD 893.23 million in 2019 and is anticipated to grow with a healthy growth rate of more than 4.2% over the forecast period 2020-2027. Lidocaine, also referred to as lignocaine, is a provincial anesthetic of the amino amide type. Lidocaine helps to reduce sharp burning pains as well as discomfort caused by skin irritations such as scratches, poison sumac, poison ivy, minor cuts, poison oak, insect bites, and sunburns. Further, lidocaine's local painkiller action foresees its use in extensive medicinal circumstances or situations that may benefit from its action, involving the treatment of impulsive ejaculation, which may reinforce the demand for lidocaine market all over the world. Also, it is frequently used in dental procedure and cosmetic surgery, for laser resurfacing after 20 minutes without occlusion. Thus, rising cosmetic surgical procedures has increased the demand for lidocaine which is primarily drives the growth of the market. For instance: as per the Victorian Cosmetic Institute, the total number of cosmetic surgical procedures in Australia estimated at around 1,790,832 in 2017 and is increased to nearly 1,811,740 in 2018. Similarly, as of 2018, nearly 53,028 Australian had done neck lifting surgery and has risen to 53,571 number of people undergone through neck lifting surgical procedure in 2019. Moreover, Lidocaine is commonly used for its anti-inflammatory actions to reduce cough and improve respiratory symptoms in severe asthmatic patients. Thus, increasing cases of chronic disease, followed by the rising geriatric population resulting in encouraging the demand for lidocaine; therefore, propelling the growth of the market. According to National Center for Biotechnology Information, generally, 33% of Chinese and 49% of Indian respondents aged 50 and older reported at least one chronic condition. As per Statista, the number of people with asthma in Australia were 2013.5 thousand people in 2005 and has risen to 2705.1 thousand peoples suffering from asthma in 2018. This, in turn, is likely to strengthen the demand for Lidocaine, thereby contributing to the market growth around the world. However, the strict regulatory standards for lidocaine is one of the prime factors restraining the market growth over the forecast period of 2020-2027.